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A series of CD81 T cell clones, specific for the IE1 epitope YPHFMPTNL, of the immediate-early protein 1 of the murine
cytomegalovirus (MCMV) were generated in order to determine their protective activity against this infection and correlate
their phenotypic markers with antiviral activity. We found that the adoptive transfer of three of these anti-MCMV CD81 T cell
clones into irradiated naive mice resulted in protection against challenge, while another CD81 T cell clone, of the same
specificity, failed to confer protection. The clones that conferred protection against lethal challenge reduced greatly viral
replication in the lung and other organs of the mice. Using one of the protective anti-MCMV CD81 T cell clones we found that
in order to be fully protective the cells had to be transferred to recipient mice no later than 1 day after MCMV challenge. The
adoptive transfer of these CD81 T cell clones also protected CD41 T-cell-depleted mice. Phenotypic characterization of the
anti-MCMV clones revealed that the nonprotective clone expressed very low levels of CD8 molecules and produced only
small amounts of TNF-a upon antigenic stimulation. Most importantly, our current study demonstrates that this MHC class
I-restricted IE1 epitope of MCMV is efficiently presented to CD81 T cell clones in vivo and further strengthens the possibility
of the potential use of CD81 T cell clones as immunotherapeutic tools against cytomegalovirus-induced disease. © 1999
Academic PressINTRODUCTION therapeutical use of these agents (Crumpacker, 1996).
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cCytomegalovirus (CMV), a member of the b-Herpes-
iridae family, is a pathogen highly prevalent in human
opulations. Human CMV (HCMV) infection is usually
symptomatic in immunocompetent hosts, but in immu-
odeficient individuals, such as organ transplant recipi-
nts and AIDS patients, the infection can develop into
evere, even fatal HCMV disease, as a result of viral
eactivation. Intrauterine transmission of HCMV has also
een shown to be a leading cause of congenital malfor-
ations (Hanshaw, 1994). The problems associated with
CMV infection have encouraged the development of
trategies for the prevention of the primary infection,
articularly of viral reactivation in immunosuppressed
ndividuals.
In organ transplant recipients, antiviral prophylaxis
ith ganciclovir can prevent HCMV reactivation and dis-
ase in a variable percentage of patients, but unfortu-
ately this treatment commonly results in severe hema-
ological disorders (Goodrich et al., 1993). Furthermore,
he increasing development of resistance of HCMV to
anciclovir and the renal toxicity associated with the use
f the new antiviral drugs are complications that limit the
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40ew effective strategies to prevent HCMV reactivation,
requent in immunosuppressed patients, could be devel-
ped based on the selective reconstitution of their im-
une system with those components that mediate pro-
ection.
HCMV reactivation occurs in 70% of seropositive
ransplant recipients, suggesting that cellular immunity,
ather than humoral immunity, might be the crucial ele-
ent in preventing HCMV reactivation (Miller et al., 1991).
urther support for the role of cellular immunity in con-
rolling HCMV reactivation was provided by the finding
hat HCMV-induced, interstitial pneumonia occurs exclu-
ively in those patients who fail to recover anti-HCMV
D81 T cell responses after receiving bone marrow
ransplants (Li et al., 1994; Reusser et al., 1991).
The role of T-cell-mediated immunity in CMV infection
as been clearly established in the murine CMV (MCMV)
odel, which resembles its human counterpart with re-
ard to viral persistence after acute infection and viral
eactivation after immunosuppression (Mocarski, 1996).
CMV infection causes severe pneumonia and fatal
ematopoietic failure in mice immunosuppressed by
-irradiation (Mutter et al., 1988; Reddehase et al., 1985).
n this model, adoptive transfer of polyclonal immune
D81 T cells into MCMV-infected irradiated recipients
ffectively controls viral replication in almost all tissues
Mutter et al., 1988; Reddehase et al., 1985, 1987, 1988;
teffens et al., 1998). In BALB/c mice, protective CD81 T
ells recognize IE1, a nonstructural protein coded by the
immediate-early gene (Volkmer et al., 1987). A series of
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41CD81 T CELL CLONES AGAINST MURINE CMVaccinia viruses expressing different fragments of this
rotein allowed the identification of the nonameric se-
uence YPHFMPTNL as the optimal IE1 epitope recog-
ized by H-2 Ld-restricted CD81 T cells (Del Val et al.,
991b). These studies provided basic principles guiding
he development of cell-mediated immunotherapy
gainst human CMV in immunosuppressed BMT recipi-
nts. In these patients, the adoptive transfer of polyclonal
cell populations must be avoided since they may po-
entially contain alloreactive cells that could contribute to
he development of a graft-versus-host reaction (Papado-
oulos et al., 1994). For this reason it is recommended
hat only HLA-matched, HCMV-specific CD81 T cell
lones be infused. Adoptive transfer of CD81 T cell
lones, specific for structural HCMV antigens, into BMT
ecipients effectively restores HCMV-specific CD81 T
ell responses to levels equivalent to those observed in
he peripheral blood of immunocompetent HCMV-sero-
ositive individuals (Riddell et al., 1992; Walter et al.,
995). More importantly, the adoptively transferred CD81
cell clones seem to protect these individuals from the
isk of HCMV reactivation, since none of the patients that
eceived these cells developed HCMV viremia or dis-
ase after cell transfer (Riddell et al., 1992; Walter et al.,
995).
In the present study we report the generation of vari-
us CD81 T cell clones specific for the immunodominant
E1 epitope of MCMV and the characterization of the
henotype and function of these clones in vitro and in
ivo. We analyzed the relationship of the phenotype of
hese clones with their in vivo antiviral activity. Our re-
ults demonstrate for the first time that CD81 T cell
lones, specific for the immunodominant IE1 epitope of
CMV, efficiently recognize this virus in several MCMV-
nfected organs and confer protection against a lethal
CMV infection. In addition, we determined the optimal
ose and time required for the successful prevention of
n otherwise lethal MCMV infection in mice, by the
doptive transfer of a IE1-specific CD81 T cell clone.
RESULTS
CD81 T cell line, specific for the immunodominant
E1 epitope, protects mice against lethal MCMV
hallenge
Twenty days after immunization with peptide YPH-
MPTNL, which corresponds to the immunodominant
E1 epitope of MCMV, lymph node cells were obtained
rom BALB/c mice and cultured with irradiated P815 cells
ulsed with the peptide. After three rounds of in vitro
timulation, the CD81 T cell line, designated L1.A, was
enerated, and 95% of the cells reacted with the IE1
eptide and secreted IFN-g, as determined by an
LISPOT assay (data not shown). To investigate the in
ivo anti-MCMV activity of this CD81 T cell line we
doptively transferred these T cells into irradiated micehallenged 4 h earlier with MCMV. As shown in Fig. 1, all
he mice that received L1.A cells were protected against
he lethal MCMV infection, surviving and remaining ap-
arently healthy for more than 30 days. In contrast, the
ontrol group of mice, which failed to receive any cells,
ied 9 to 11 days after challenge. Similarly, mice that
eceived by adoptive transfer an unrelated CD81 T cell
lone, Y26, specific for and protective against malaria
Rodrigues et al., 1990), failed to become protected
gainst MCMV challenge.
he antiviral activity of certain IE1-specific CD81 T
ell clones
By limiting dilution, a series of 18 T cell clones was
erived from the L1.A T cell line. These clones were
creened for their antigen and epitope specificity, using
n ELISPOT assay. They were also screened for the
xpression of a/bTCR, CD3, and CD8 molecules. Based
n preliminary results obtained by the adoptive transfer
f some of these clones, we chose four IE1-specific
lones for further characterization.
The selected CD81 T cell clones were adoptively
ransferred into irradiated mice, and the survival of these
nimals after their inoculation with MCMV was moni-
ored. Distinct CD81 T cell clones consistently displayed
onsiderable differences in the level of their in vivo
rotective activity. Adoptive transfer of clones C29, C1,
nd C3 conferred protection to 100% and close to 75 and
0% of MCMV-infected irradiated mice, respectively,
hile consistently no protection was observed in mice
eceiving clone C25. Table 1 displays the results of one
xperiment, representative of several performed under
dentical conditions. To gain further and more quantita-
ive insight into the inhibitory effect on MCMV replication
f the adoptive transfer of these diverse CD81 T cell
FIG. 1. Protective anti-MCMV effect of adoptively transferred T cell
ine L1.A. Mice irradiated with 600 rad were infected iv with 105 PFU of
CMV. Four hours later, groups of mice received 1.2 3 107 cells from
he L1.A T cell line or the same number of cells from an anti-malaria
lone, Y26. A control group of mice did not receive any cells. Survival
f these MCMV-infected mice was monitored for 4 weeks after virus
noculation. Each experimental group consisted of four mice, and the
esults correspond to those obtained in one of two identical experi-
ents.
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42 FERNANDEZ, ZAVALA, AND TSUJIlones we measured the amount of infectious virus in the
ung, liver, adrenal glands, and spleen of the irradiated,
nfected mice. Viral titers in these diverse organs were
etermined by a plaque assay 7 days after challenge, as
escribed under Materials and Methods. In MCMV-in-
ected mice injected with clones C29, C1, or C3 we found
marked reduction of viral titers in all the organs that
ere tested, compared to those of control MCMV-in-
ected mice. Clone C29 had the greatest effect on the
iral load in the lungs (Fig. 2), while in the other organs
ll three protective clones inhibited viral replications that
esulted in 10- to 100-fold reduction of viral titers com-
ared to those of control, infected mice (data not shown).
n sharp contrast, no such reductions were observed in
he organs of mice that had received the nonprotective
lone C25 (Fig. 2).
henotype and in vitro activity of the MCMV-specific
D81 T cell clones
The phenotype of these four MCMV-specific CD81 T
ell clones was characterized, and their in vitro activities
ere determined. All four clones were capable of lysing
arget cells in the presence of the IE1 epitope peptide, as
etermined by 51Cr release assay. However, the individ-
al clones exhibited different levels of cytotoxic activity.
he nonprotective clone C25 displayed the lowest per-
entage of 51Cr released at different incubation times
Fig. 3A) and with different doses of the peptide (Fig. 3B).
All four clones recognized the IE1 epitope in the con-
ext of the H-2 Ld molecule, since they reacted with
eptide-pulsed RMAS-Ld cells, but not RMAS-Kd cells, as
etermined by an ELISPOT assay (data not shown). As
or lymphokine secretion, we found that all the clones
roduce similar amounts of IFN-g upon in vitro restimu-
Protective Effect of Adoptively Transferred MCMV-Specific
CD81 T Cell Clones
CD81 T cell clone
Protected mice/
total challenged
Percentage of
survival (%)
Experiment 1
None 0/4 0
C29 4/4 100
C1 3/4 75
C3 3/4 75
C25 0/4 0
Experiment 2
None 0/4 0
C29 4/4 100
C1 3/4 75
C3 2/4 50
C25 0/4 0
Note. All mice were irradiated (600 rad) and infected iv with 105 PFU
f MCMV. Four hours after the infection, 1.2 3 107 cells of the respective
CMV-specific T cell clones were adoptively transferred into experi-
ental groups. Control mice did not receive any cells.NF-a produced by the four clones varied greatly, with
he lowest amounts of TNF-a being produced by the
onprotective clone C25 (Fig. 4). FACS analysis revealed
hat all four clones express the Vb9 subset of the T cell
eceptor and that although all clones express CD8 mol-
cules, clone C25 expresses significantly lower levels of
D8 molecules on its surface (Table 2). It had been
emonstrated that the levels of expression of CD44 and
LA-4 correlate with the protective capacity of CD81 T
ells against a malaria infection in mice (Rodrigues et al.,
992). However, we found no correlation between the
evel of expression of these and some other adhesion/
ctivation molecules and the anti-MCMV activity of the
our clones (Table 2).
ose and time dependence of in vivo antiviral activity
f clone C29
To determine the dose dependency of the protective
ffect of adoptively transferred CD81 T cell clones we
elected clone C29 because it displayed the strongest
rotective effect. As documented in Table 3, the adoptive
ransfer of 1.2 3 107 or more C29 cells considerably
esulted in 100% protection against a MCMV challenge.
ortality was reduced by 50% when 6 3 106 cells of this
lone were transferred into MCMV-infected mice. How-
ver, adoptive transfer of 3 3 106 cells of clone C29 failed
o reduce the lethality of MCMV infection, but it pro-
onged significantly the survival time of the recipient
ice, compared to the control group. We did not observe
FIG. 2. Reduction of MCMV titers in the lung after adoptive transfer
f four CD81 T cell clones. Twelve million cells of the respective T cell
lones were adoptively transferred into groups of irradiated MCMV-
nfected mice 4 h after virus inoculation. A control group of mice did not
eceive any cells. Viral titers in the lung of these mice were determined
days after the cell transfer. The results reflect two identical experi-
ents and are expressed as averages 6 SD of four mice.
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43CD81 T CELL CLONES AGAINST MURINE CMVny reduction in body weight or any other macroscopic
anifestations suggestive of a pathological reaction
aused by the adoptively transferred CD81 T cell clones
n both MCMV-infected and uninfected mice (data not
hown).
FIG. 3. (A) In vitro cytolytic activity of four CD81 T cell clones all reco
ere incubated with 51Cr-labeled P815 target cells pulsed with 1 mM IE
ells was measured at the time points indicated in the figure. (B) In vit
ifferent doses of the peptide. MCMV-specific T cell clones were i
oncentrations of IE1 peptide at an effector to target ratio of 5:1. In bo
n three different occasions and are expressed as averages 6 SE of t
P , 0.05) lower than that of the rest of the clones, is marked with as
FIG. 4. Level of secretion of IFN-g and TNF-a by four MCMV-specific
rom each of the four clones were cultured in 96-well plates in the pre
cells were cultured with the peptide, under the same conditions as d
he absence of the peptide. The supernatant fluids were removed 24
upernatant were determined by ELISA, as described under Materials a
s averages 6 SE of triplicated cultures.The protective effect of clone C29 was also highly
ependent on how long after the MCMV challenge these
loned CD81 cells were administered (Table 4). Com-
lete protection was achieved when the adoptive trans-
er was performed up to 24 h after challenge, but no
the IE1 epitope at different time points. MCMV-specific T cell clones
tide at an effector to target ratio of 5:1. The release of 51Cr from target
ytic activity of four IE1-specific CD81 T cell clones in the presence of
d for 6 h with 51Cr-labeled P815 target cells pulsed with different
d B, the data represent one of three almost identical results obtained
d cultures. The cytolytic activity of clone C25, which was significantly
T cell clones. For IFN-g determination, 105 IE1-specific CD81 T cells
of 1 mM IE1 peptide. For determination of TNF-a secretion, 106 CD81
ed above. As controls, we used the same cloned T cells incubated in
the incubation, and the amounts of IFN-g and TNF-a in the culture
thods. The results reflect two identical experiments and are expressedgnizing
1 pep
ro cytol
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th A an
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sence
escrib
h after
nd Me
r
t
e
t
c
t
t
w
s
b
c
a
8
r
TABLE 2
L
T
A
f
M
w
n
p
r
c
TABLE 4
4
1
2
4
6
N
m
c
c
p
r
M
n
a
w
m
p
r
44 FERNANDEZ, ZAVALA, AND TSUJIeduction in mortality was observed when the cells were
ransferred 2 or more days after MCMV inoculation. How-
ver, we observed a significant increase in the survival
ime of mice that received clone C29 48 h after MCMV
hallenge.
To determine the length of time that the in vivo persis-
ence of cells from clone C29 was required to fight off
his viral infection, MCMV-infected, C29 recipient mice
ere injected with a monoclonal anti-CD8 antibody. As
hown in Table 5, we found that the protection conferred
y clone C29 was completely abolished when CD81 T
FACS Analysis of the Expression of Various T Cell Surface
Molecules on MCMV-Specific CD81 T Cell Clones
Phenotypic
marker
CD81 T cell clone
C1 C3 C29 C25
evel of in vivo protection 1 1 111 2
cell receptor Vb region Vb9 Vb9 Vb9 Vb9
ctivation/adhesion molecules
—a 5b 5 3 2
CD4 4 4 3 2
CD8 229 154 142 10
CD2 6 8 21 96
CD3 82 94 107 140
CD44 82 40 91 72
VLA-4 10 4 19 72
LFA-1 392 320 312 251
ICAM-1 25 15 21 23
MEL-14 4 4 3 3
a Background staining with secondary antibody.
b The relative mean of fluorescence obtained with mAb is indicated
or the four clones tested.
TABLE 3
Anti-MCMV Protective Effect of Clone C29 upon Its Adoptive
Transfer with Different Numbers of Cells
Number of C29
cells transferreda
Protected mice/
total challengedb
Survival
(%)
Mean time to
deathc (days)
483106 8/8 100 —
243106 8/8 100 —
123106 8/8 100 —
63106 4/8 50 14.0 6 1.4d
33106 0/8 0 11.8 6 1.3d
0 0/8 0 9.5 6 0.3
a All mice were irradiated (600 rad) and challenged iv with 105 PFU of
CMV. Four hours after the infection, the indicated numbers of cells
ere adoptively transferred into experimental groups. Control mice did
ot receive any cells.
b Results of two combined experiments.
c Refers to those mice that were not protected. Results are ex-
ressed as the mean 6 SD of eight mice.
d The mean time to death was significantly (P , 0.01) delayed in the
ecipient animals compared with that in control groups, reflecting a
onsiderable decrease of their viral loads.ells, including C29 cells, were depleted for up to 4 days
fter cell transfer and MCMV challenge. Depletion at 6 or
days after the adoptive transfer reduced the survival
ate of CMV challenged mice to 50%.
Anti-MCMV Protective Effect of Clone C29 Adoptively Transferred
at Different Times after MCMV Infection
Time of cell
transfer after
MCMV
infectiona
Protected mice/
total challengedb
Survival
(%)
Mean time to
deathc (days)
h 8/8 100 —
day 8/8 100 —
days 0/8 0 13.6 6 0.3d
days 0/8 0 9.6 6 0.3
days 0/8 0 9.9 6 0.1
o transfer 0/8 0 9.8 6 0.2
a Challenge of mice was performed as described in Table 3. Twelve
illions cells of clone C29 were adoptively transferred into MCMV-
hallenged mice at the times indicated. Control mice did not receive
ells. Survival was monitored for 4 weeks after the infection.
b Results of two combined experiments.
c Refers to those mice that were not protected. Results are ex-
ressed as the mean 6 SD of eight mice.
d The mean time to death was significantly (P , 0.01) delayed in the
ecipient animals compared with that in control groups.
TABLE 5
Effect of CD81 T Cell Depletion on the Anti-MCMV Activity of
Adoptively Transferred Clone C29
Adoptive
transfer of
C29 cellsa
Injection of
anti-CD8 mAbb
(after adoptive
transfer)
Mortalityc
(%)
Mean time to
deathd (days)
1 — 0 —
2 — 100 11.5 6 0.6
1 2 h 100 12.5 6 1.9
1 2days 100 13.3 6 1.5
1 4days 100 14.5 6 1.3
1 6days 50 16.0 6 1.6e
1 8days 50 16.3 6 1.0e
1 12days 25 20.7 6 0.6e
a Twelve million cells of clone C29 were transferred into groups of
CMV-infected irradiated mice at 4 h after infection. Control groups did
ot receive any cells.
b After adoptive transfer, groups of mice were injected ip with an
nti-CD8 monoclonal antibody at the times indicated. Surviving mice
ere monitored for up to 30 days after the infection.
c The results represents two combined experiments. Each experi-
ental group consisted of four mice.
d Refers to those mice that were not protected. Results are ex-
ressed as the mean 6 SD of eight mice.
e The mean time to death was significantly (P , 0.01) delayed in the
ecipient animals compared with that in control groups.
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45CD81 T CELL CLONES AGAINST MURINE CMVlone C29 confers protection against lethal MCMV
hallenge in the absence of CD41 T cells
The findings of some studies on human CMV infection
uggest that in order to obtain an optimal cell-mediated
nti-CMV response upon adoptive transfer of CD81 T
ells, comparable levels of CMV-specific CD41 T cells
re required (Walter et al., 1995). To investigate this in the
urine model, mice were injected with a monoclonal
nti-CD4 antibody every 10 days, starting 3 days before
nd ending 27 days after the adoptive transfer of clone
29 into MCMV-infected animals. This protocol allowed
s to deplete more than 95% of the CD41 T cells that
emain after irradiation of the mice and prevent the
econstitution of the CD41 T cell subset after repopula-
ion of the bone marrow (data not shown). As shown in
ig. 5, both normal and CD4-depleted mice that received
lone C29 were fully protected for at least 4 weeks after
he MCMV infection, while all control animals died by
ay 11 after challenge. These results indicate that the
doptive transfer of clone C29 to mice confers complete
rotection against MCMV infection, without requiring the
resence of CD41 T cells.
DISCUSSION
Several lines of evidence indicate that CD81 T cells
lay an important role in the protective immune response
gainst cytomegaloviruses. In humans, the lack of CMV-
pecific CD81 T cell responses in recipients of bone
arrow transplants correlates with an increased risk of
MV reactivation (Li et al., 1994; Reusser et al., 1991). In
urine CMV infections CD81 T cells have also been
hown to play a protective role. This protection was
emonstrated by the survival of irradiated MCMV-in-
ected mice that were recipients of adoptively transferred
olyclonal immune CD81 T cells (Mutter et al., 1988;
FIG. 5. Effect of CD41 T cell depletion on the anti-MCMV protective
ctivity of clone C29. Twelve million cells of clone C29 were injected
nto groups of MCMV-infected, irradiated mice. Another experimental
roup was serially depleted of CD41 T cells by injecting an anti-CD4
Ab every 10 days, starting 3 days before the infection and the
doptive transfer of the cloned cells. A control group did not receive
ny cells. Each group consisted of four mice, and the results represent
hose obtained in one of two similar experiments.n the most recent studies, this protection was assessed
y PCR measuring the level of latent viral DNA in differ-
nt organs (Steffens et al., 1998).
A MCMV antigen, the phosphoprotein 89 IE1, recog-
ized by protective CD81 T cells, has been identified and
loned into a vaccinia virus. The immunization of naive
ice with this recombinant vaccinia virus, expressing
he MCMV phosphoprotein 89, induced substantial pro-
ection against a lethal MCMV challenge (Jonjic et al.,
988; Del Val et al., 1991b). Earlier adoptive transfer
xperiments were done using polyclonal MCMV-specific
D81 T cell lines, and these bulk cell lines were shown
o confer protection against this infection.
In the present study the adoptive transfer of various
rotective CD81 T cell clones, specific for the H-2
d-restricted epitope YPHFMPTNL of IE1, the phospho-
rotein 89 of murine CMV, was shown to protect mice
rom an otherwise lethal MCMV challenge, demonstrat-
ng that this antigen is appropriately processed and
resented in these viral infected mice. Adoptive transfer
f one of the MCMV-specific CD81 T cell clones, C29,
evealed that its protective activity was not dependent on
he presence of CD41 T cells, since irradiated recipient
ice survived after depletion of CD41 T cells, i.e., in the
bsence of this T cell subset. This is of interest since it
iffers from certain observations in clinical trials in which
ersistence of protection, conferred by transferred CD81
cell clones, was found to correlate with the presence of
MV-specific CD41 T cell responses (Walter et al., 1995).
Clinical studies in BMT recipients indicate that the
arly recovery of CMV-specific T cell responses is es-
ential for a favorable outcome in immunosuppressed
ecipients, which otherwise run a considerable risk of
MV reactivation (Herstentein et al., 1995). Previous
tudies in mice had shown that the adoptive transfer of
olyclonal CD81 T cells limits viral replication in the lung
hen the cells are transferred “early” in the infection, 2 h
prophylactic schedule), or “late,” 6 days after the infec-
ion (therapeutic schedule) (Reddehase et al., 1987). We
bserved that the adoptive transfer of MCMV-specific T
ell clones to mice completely prevents virus-induced
ethality when these cells are injected into mice no later
han 1 day after the MCMV challenge. However, adoptive
ransfer of these cells at 48 h after MCMV challenge
ailed to protect the mice from a lethal outcome of this
nfection (Table 4). One possible explanation for this
inding is that the viral load at this time becomes so large
hat the CD81 T cells can no longer control MCMV
eplication. Furthermore it is likely that infected tissues
uch as the bone marrow may, some time after chal-
enge, no longer be able to recover from the pathology
aused by this viral infection. Therefore our results sup-
ort the notion that adoptive immunotherapy to prevent
uman CMV reactivation by using CD81 T cell clones is
ikely to be more effective if the cells are transferred
rophylactically, rather than therapeutically.
We found that protective cloned C29 T cells had to
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46 FERNANDEZ, ZAVALA, AND TSUJIersist in vivo for at least 1 week after cell transfer in
rder to prevent death of 50% of the challenged mice. In
act, there is a crucial time period of up to 4 days after
doptive transfer in which the cloned CD81 T cells dis-
lay maximal anti-MCMV activity, conferring protection
gainst this viral infection. The depletion of CD81 T cells
uring this period completely abolished their protective
ctivity (Table 5). These results indicate that presentation
f the MCMV epitope persists in most cells for at least 4
ays after infection. This finding raises the question of
hether shortly after MCMV infection there is a down-
egulation of class I MHC molecules in vivo. This has
een widely interpreted as a phenomenon that allows
he virus to persist, because CD81 T cells would not be
ble to recognize MCMV antigens on infected cells in the
bsence of class I MHC molecules. Therefore, it would
e of interest to further investigate whether class I MHC
own-regulation really occurs in vivo and, if so, whether
his affects specifically some cell types. For instance, it
as already been shown that peritoneal macrophages
rom MCMV-infected SCID mice exhibit enhanced cell
urface expression of class I MHC molecules, even after
days of infection (Heise and Virgin, 1995). This is of
nterest since there is experimental evidence indicating
hat monocytes/macrophages are susceptible to MCMV
nfection in vivo and that these monocytes/macrophages
ediate MCMV dissemination between organs during
rimary infection (Stoddart et al., 1994).
The adoptive transfer of CD81 T cell clones of the
ame IE1 epitope specificity revealed clear differences
n the level of their protective activity. While clone C29
onferred protection to 100% of the mice, clones C1 and
3 protected only a certain percentage of mice against a
ethal MCMV infection. In sharp contrast, clone C25
ailed to protect any of the infected mice. The protective
ffect of the adoptive transfer of these clones correlated
ith their ability to reduce viral loads in vivo. Protective
lones C1, C3, and C29 significantly inhibited the repli-
ation of the virus in various tissues, while clone C25
ailed to decrease the viral loads in any of the organs we
xamined. Clone 29, which prevented lethality in 100% of
he mice, was most effective in reducing the viral load in
he lungs (Fig. 2). The various protective clones (C1, C3,
nd C29) reduced the viral loads to similar levels in the
ther organs we examined.
It has been suggested that T cell clones may possess
pecific tissue and organ tropisms and display different
ffector functions (Ando et al., 1994; Baron et al., 1993). In
his study we show that adoptive transfer of a single
D81 T cell clone causes a reduction of viral titers in
everal different organs. This observation indicates that
hese cloned CD81 T cells recirculate in vivo, exerting
heir anti-MCMV activity in various different organs.
CMV exhibits different patterns of reactivation when
ifferent organs are transplanted into an immunosup-
ressed host (Ho, 1991). Thus, the fact that the adminis-nhibition of MCMV replication in several tissues ap-
ears to indicate that CD81 T cell clones could be useful
s immunotherapeutic tools to prevent HCMV reactiva-
ion following different organ transplants.
In the malaria system, CD81 T cell clones of the same
pitope specificity, and with comparable levels of cyto-
oxic activity and lymphokine secretion profiles in vitro,
ere found to differ greatly in their in vivo effector func-
ion (Rodrigues et al., 1992). This difference correlated
ith the level of expression of certain adhesion mole-
ules, namely CD44 and VLA-4 (Rodrigues et al., 1992).
owever, in the current study, we detected no correlation
etween the level of expression of these molecules and
he protective capacity of the respective CD81 T cell
lones.
One of the interesting findings was that the nonpro-
ective clone C25 expressed minimal levels of the CD8
olecules on its surface. Furthermore, clone C25 exhib-
ted lower cytolytic activity in vitro than the three protec-
ive clones. This clone also secretes the lowest amounts
f TNF-a in response to peptide stimulation (Fig. 4). It is
ell known that the CD8 molecule functions as a core-
eptor for MHC class I molecules and facilitates T cell
ctivation through its interaction with p56 lck tyrosine
inase (Norment et al., 1988; Van Oers et al., 1992).
ecently, it has been demonstrated that CD8, especially
ts b chain, strengthens TCR-ligand binding, thereby
odulating the TCR-mediated T cell activation (Renard et
l., 1996). In view of these findings it is possible that due
o its low levels of expression of CD8, clone C25 may not
e adequately activated by MCMV-infected cells. While
here is no information regarding the effector mecha-
isms by which CD81 T cells control the MCMV infec-
ion, TNF-a has been shown to play an inhibitory role in
CMV replication both in vitro and in vivo (Lucin et al.,
994; Pavic et al., 1993). Therefore, low levels of produc-
ion of TNF-a by the nonprotective clone C25 may con-
ribute to the lack of its antiviral activity. Alternatively, the
ombination of low levels of both CD8 and TNF-a, and/or
ther factors, might be the basis for the failure of certain
D81 T cell clones, such as clone C25, to confer pro-
ection. Further studies are required to determine the
ole of TNF and other potential effector molecules in
D81 T-cell-mediated protection against MCMV, by us-
ng knock-out mice lacking corresponding molecules. In
rief, the studies will be done by transferring MCMV-
pecific CD81 T cell clones into MHC-matched, MCMV-
nfected knock-out mice lacking the receptor for TNF and
ther cytokines or by transferring MCMV-specific T cell
lones obtained from TNF or other knock-out mice into
HC-matched, MCMV-infected wild-type mice.
In conclusion, the current results demonstrate that the
n vivo protective capacity of a given MCMV specific
D81 T cell clone does not depend solely on the fine
pitope specificity of these T cells. Further characteriza-
ion of the factors that determine the potential of T cell
clones to protect virus-infected hosts should broaden our
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47CD81 T CELL CLONES AGAINST MURINE CMVnderstanding of CD81 T-cell-mediated protective mech-
nisms and lead to the development of an effective
mmunotherapy for infections caused by HCMV and per-
aps other intracellular microbial agents as well.
MATERIALS AND METHODS
iruses and animals
Six to 8-week-old female Balb/c mice used in these
tudies were purchased from The Jackson Laboratories
Bar Harbor, ME). MCMV (Smith Strain, American Type
ulture Collection) was maintained as a tissue culture-
assage stock and stored at 270°C, as previously de-
cribed (Heise and Virgin, 1995). For mouse inoculation,
he MCMV was thawed on ice and diluted in DMEM
ulture medium, supplemented with 5% fetal calf serum
FCS) and 0.2 mM EDTA. After the culture was centri-
uged at 500 g for 5 min, all mice were injected intrave-
ously with culture supernatant containing 1 3 105 PFU
f MCMV per dose.
ynthetic peptides and immunization
Peptides were synthesized by standard procedures,
sing the tBOC methodology described by Merrifield
1986). The IE1 epitope (YPHFMPTNL) is a H-2d-re-
tricted CTL epitope, present between aa 168 and 176 of
he phosphoprotein 89 of MCMV (Del Val et al., 1991a).
he B-4 epitope (KQIRDSITEEWS) is a H-2d-restricted T
elper epitope contained between aa 249 and 260 of the
lasmodium berghei circumsporozoite protein (Romero
t al., 1988). For immunization, mice were injected sub-
utaneously with 20 mg of the peptide representing the
E1 epitope and 20 mg of the T helper epitope, both
mulsified in incomplete Freund’s adjuvant (IFA). The T
elper sequence was included in the emulsion to in-
rease the number of CD81 T cells primed by the syn-
hetic peptide, as reported elsewhere (Widmann et al.,
992).
eneration and cloning of the MCMV-specific CD81 T
ymphocytes
A series of CD81 T cell clones was generated from
ymph node cells of BALB/c mice immunized with the
eptides. Ten days after immunization, lymph node cells
btained from peptide-immunized animals were stimu-
ated in vitro with irradiated P815 cells, pulsed with a 1
M concentration of the peptide corresponding to the
E1 epitope. These cells were restimulated weekly in the
resence of irradiated syngeneic spleen cells and irra-
iated peptide pulsed P815 cells. The T cell line was
aintained in DMEM supplemented with 10% FCS and a
% supernatant of PMA-activated EL-4 lymphoma T cells
s source of IL-2 and IL-4. Cloning of the T cells was
arried out by the limiting dilution technique. Once es-
ablished, the clones were restimulated weekly with ir-ulsed P815 cells. The generation and maintenance of
lone Y26, specific for an epitope contained in the CS
rotein, a malarial antigen, have been described else-
here (Rodrigues et al., 1990).
MV challenge and adoptive transfer of CD81 T cell
ines and clones
For challenge, all mice were subjected to a sublethal
ose, 600 rad, of g-irradiation, and 1 h later, the mice
ere injected intravenously with 105 PFU of CMV. For the
doptive transfer experiments, cloned CD81 T cells were
arvested a week after their restimulation, and after
ashing in DMEM, the desired numbers of cloned T
ells were injected intravenously into the mice. Adoptive
ransfer of these cells was performed 4 h after the CMV
nfection, unless otherwise indicated.
hromium release assay
This assay was performed as described elsewhere
Rodrigues et al., 1990). Briefly, 51Cr-labeled P815 cells,
n H-2d mastocytoma, were pulsed with a 1 mM concen-
ration of the peptide representing the IE1 epitope and
hen cocultured at 37°C with the cloned CD81 T cells, at
n effector to target ratio of 5:1, and the 51Cr release was
easured at different times after coculture, as indicated.
he results are expressed as the mean values from
uplicate culture wells.
low cytometric analysis and mAb
One million cloned T cells were incubated for 45 min
t 4°C with purified mAbs directed against different cell
urface markers. After repeated washings, these cells
ere incubated with FITC-labeled goat anti-rat IgG or
oat anti-hamster IgG, and after additional washings the
ells were fixed in PBS containing 2% (w/v) paraformal-
ehyde. The fluorescence was analyzed using a FACS-
an cytometer (Rodrigues et al., 1992).
The following antibodies were used for staining of the
loned CD81 T cells: anti-TCR a/b (H-57-597), anti-CD2
RM2-5), anti-CD4 (H129.19), anti-CD8b (53-5.8), anti-VLA-
/LPAM-1 (R1-2), all purchased from Pharmingen (San
iego, CA); rat anti-mouse IgG purchased from American
ype Culture Collection (Rockville, MD) included anti
FA-1 (FD441.8), anti-L-selectin (MEL-14), anti-ICAM 1
YN1/1.7.4), anti-CD44 (KM 703, KM 201). Mouse IgG
ntibodies anti-Vb2 (B20.6), anti-Vb 5.1 1 5.2 (MR 9-4),
nti-Vb7 (TR 130), anti-Vb8 (1 1 2 1 3) (F23.1), anti-Vb9
MR 10-2), anti-Vb11 (RR 3-15), anti-Vb12 (MR 11-2), anti-
b13 (MR-124), and anti-Vb14 (4-2) and rat IgG anti-
ouse Vb3 (KJ 25), anti-Vb4 (KT4-10), and anti-Vb11
KT11-14.2) antibodies were kindly provided by Dr.
tanislav Vukmanovic (New York University, New York).
Viral titration in organs
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48 FERNANDEZ, ZAVALA, AND TSUJIFor titration of viral stocks, 100 ml of the supernatants
f 10-fold serial dilutions of the virus was plated on 90%
onfluent monolayers of 3T3 fibroblasts in 48-well tissue
ulture plates. After 1 h of incubation, the plates were
verlaid with 1 ml of DMEM, 5% FCS plus 1% methylcel-
ulose and incubated for 4 days until plaques appeared.
o determine the viral levels presented in infected or-
ans, these organs were harvested 7 days after infec-
ion, weighted, minced, and homogenized on ice in 1 ml
f DMEM, 10% FCS. The organ homogenates were then
liquoted and frozen at 270°C. Prior to titration, organ
omogenates were thawed on ice, sonicated, and cen-
rifuged at 500 g for 5 min, and 100 ml of the supernatants
f the 10-fold dilution of the samples was plated on 3T3
ibroblasts. To enhance the sensitivity of the assay, these
lates were centrifuged for 30 min at 800 g (Hudson et
l., 1976). After centrifugation, the plates were overlaid
ith DMEM, 5% FCS and 1% methyl cellulose and incu-
ated under the same conditions described above. Viral
laques were counted 4 days later.
easurement of IFN-g and TNF-a production by
LISA
Eight days after restimulation, 1 3 105 cloned CD81 T
ells (or 1 3 106 cloned CD81 T cells for TNF-a deter-
ination) per well were incubated with 1 mM IE1 peptide,
n a final volume of 200 ml. The same number of cells
ncubated without the peptide was used as control. After
4 h of incubation, the supernatants were collected and
he amount of each lymphokine was determined by a
andwich ELISA, as described (Yang and Hayglass,
993). For this assay the following monoclonal antibod-
es were used: R4 (anti-IFN-g, capture), biotinylated
MG1.2 (anti-IFN-g, detection), G281-2626 (anti-TNF-a,
apture), and biotinylated MP6-XT3 (anti-TNF-a, detec-
ion), all purchased from Pharmingen. Recombinant
FN-g and rTNF-a (Genentech, South San Francisco, CA)
ere used as positive controls in these assays.
LISPOT assay
The ELISPOT assay for the detection of epitope-spe-
ific IFN-g-secreting cells was performed essentially as
reviously described (Miyahira et al., 1995; Rodrigues et
l., 1997). Briefly, 96-well nitrocellulose plates (Multi-
creen HA, Millipore Corp., Bedford, MA) were coated
ith anti-mouse IFN-g mAb, R4. After overnight incuba-
ion at room temperature, the wells were washed several
imes with culture medium and incubated for more than
h at 37°C. Serially diluted cloned T cells were cocul-
ured for 24 to 28 h at 37°C in 5% CO2 with 10
5 target
ells, pulsed with the synthetic peptide representing the
D81 T cell epitope. Target cells, not pulsed with the
eptide, were used as negative controls. After extensive
ashing with PBS/0.05% Tween 20, the plates were in-MG1.2, followed by incubation with peroxidase-labeled
treptavidin (Kirkegaard & Perry Laboratories, Gaithers-
urg, MD). The spots were developed by adding a solu-
ion of 50 mM Tris, at pH 7.5, containing 1 mg/ml of the
ubstrate 3.39-diaminobenzidine tetrahydrocloride dehy-
rate and 0.5 ml/ml of 30% H2O2. After 10 to 15 min, the
umber of spots corresponding to IFN-g-secreting cells
as determined using a stereomicroscope.
n vivo depletion of CD41 and CD81 T cell subsets
To deplete CD81 T cells, mice received multiple intra-
eritoneal (ip) injections of anti-CD8 mAb, YTS 169, with
ach dose consisting of 1.5 mg. The injection of this
ntibody into MCMV challenged mice was performed at
ifferent times after the adoptive transfer of the CD81 T
ell clone, as indicated. To deplete CD41 T cells, mice
ere injected ip with 1 mg of anti-CD4 mAb, GK1.5, six
imes every 10 days, starting 3 days before the CMV
hallenge and the adoptive transfer of a CD81 T cell
lone.
tatistical analysis
The statistical analysis of the data was performed by
sing the one-way ANOVA test.
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